Clinical Trial Detail

NCT ID NCT02818920
Title Neoadjuvant Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Neal Ready
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.